Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip W Kantoff

Showing results (1-10 of 361) with videos related to

Pageof 37
Sort By:
Urology|September 17, 2002
Chemotherapy for prostate cancerTimothy Gilligan, Philip W Kantoff
The Urologic Clinics of North America|October 23, 2012
Immunotherapy for castration-resistant prostate cancerGuru Sonpavde, Philip W Kantoff
Oncology (Williston Park, N.Y.)|April 3, 2007
Hormone-refractory prostate cancer: choosing the appropriate treatment optionRobert W Ross, Philip W Kantoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2006
Noise and bias in microarray analysis of tumor specimensPhillip G Febbo, Philip W Kantoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Changes in PSA kinetics after DNA vaccine therapy-not so fast!Matthew R Smith, Philip W Kantoff
The New England Journal of Medicine|October 17, 2003
Prevention of prostate cancer with finasterideMark A Rubin, Philip W Kantoff
Seminars in Oncology|October 23, 2003
Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligandsStacey B Leibowitz, Philip W Kantoff
Nature Clinical Practice. Urology|December 19, 2007
Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?Steven M Corsello, Philip W Kantoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Predicting outcomes in prostate cancer: how many more nomograms do we need?Robert W Ross, Philip W Kantoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?Lorelei A Mucci, Philip W Kantoff
Pageof 37

Showing results (1-10 of 361) with videos related to

Sort By:
Pageof 37
Urology|September 17, 2002
Chemotherapy for prostate cancerTimothy Gilligan, Philip W Kantoff
The Urologic Clinics of North America|October 23, 2012
Immunotherapy for castration-resistant prostate cancerGuru Sonpavde, Philip W Kantoff
Oncology (Williston Park, N.Y.)|April 3, 2007
Hormone-refractory prostate cancer: choosing the appropriate treatment optionRobert W Ross, Philip W Kantoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2006
Noise and bias in microarray analysis of tumor specimensPhillip G Febbo, Philip W Kantoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Changes in PSA kinetics after DNA vaccine therapy-not so fast!Matthew R Smith, Philip W Kantoff
The New England Journal of Medicine|October 17, 2003
Prevention of prostate cancer with finasterideMark A Rubin, Philip W Kantoff
Seminars in Oncology|October 23, 2003
Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligandsStacey B Leibowitz, Philip W Kantoff
Nature Clinical Practice. Urology|December 19, 2007
Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?Steven M Corsello, Philip W Kantoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Predicting outcomes in prostate cancer: how many more nomograms do we need?Robert W Ross, Philip W Kantoff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?Lorelei A Mucci, Philip W Kantoff
Pageof 37